Novel mechanisms that prevent SLE

The Defense Health Agency (DHA) awarded a $300,000 Project Grant to the Hospital for Special Surgery on September 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) for research titled "Novel Mechanisms That Prevent SLE" (Systemic Lupus Erythematosus). The award, which extends through August 31, 2027, will support biomedical research conducted at the awardee's New York, NY facility to investigate novel preventive mechanisms for systemic lupus erythematosus, an autoimmune disease. This research aligns with the DHA's broader portfolio of basic, applied, and advanced biomedical research initiatives designed to advance medical solutions and improve health outcomes for Service Members and the general public.

As a recognized leader in rheumatology and autoimmune disease research, the Hospital for Special Surgery will leverage its clinical and research expertise to conduct this two-year investigator-initiated project. The research builds upon the institution's track record of federal funding in lupus-related investigations and represents a continuation of the DHA's commitment to funding innovative approaches to complex autoimmune conditions affecting the military and civilian populations.